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Abstract: Overactive bladder (OAB) is a prevalent and costly condition that can affect any 
age group. Typical symptoms include urinary urgency, frequency, incontinence and nocturia. 
OAB occurs as a result of abnormal contractions of the bladder detrusor muscle caused by the 
stimulation of certain muscarinic receptors. Therefore, antimuscarinic agents have long been 
considered the mainstay of pharmacologic treatment for OAB. Currently, there are ﬁ  ve such 
agents approved for the management of OAB in the United States: oxybutynin, tolterodine, 
trospium, solifenacin and darifenacin. This article summarizes the efﬁ  cacy, contraindications, 
precautions, dosing and common side effects of these agents. All available clinical trials on 
trospium, solifenacin and darifenacin were reviewed to determine its place in therapy.
Keywords: overactive bladder, urinary incontinence, pharmacologic management, antimus-
carinic agents, anticholinergics
Introduction
Overactive bladder (OAB) is a clinical condition characterized by urinary urgency with 
or without incontinence, urinary frequency and nocturia (Abrams 2002; Ouslander 
2004). Patients with OAB typically present with symptoms of a sudden and compel-
ling need to urinate which is difﬁ  cult to defer (urgency), involuntary leakage of urine 
with feelings of urgency (urge urinary incontinence), frequency ( 8 micturitions in 
24 hours) and nocturia (  one awakening per night to void) (Herbison 2003). In ad-
dition, patients with OAB tend to display poor health status, activity restriction, social 
isolation, depressive symptoms and decreased quality of life (Herbison 2003; Stewart 
2003; Ouslander 2004; Chu 2006 and Staskin 2006). OAB affects approximately 17% 
of the population in the United States. Although incidence increases with advanced 
age, OAB may affect individuals of all age groups (Stewart 2003). In 2000, the direct 
and indirect expenses associated with OAB were about $12 billion. The burden of 
diagnosis and treatment contributed to only 0.6% ($78 million) and 23% ($2.8 billion) 
of the total costs, respectively (Hu 2003).
OAB occurs as a result of abnormal and involuntary contractions of the detru-
sor muscle in the bladder, which is embedded by muscarinic receptors (M2 and M3 
subtypes). Stimulation of M2 and M3 receptors by acetylcholine causes bladder con-
tractions that leads to urination (Chu 2006 and Erdem 2006). Normally, the detrusor 
muscle remains at rest as the bladder is ﬁ  lled by urine (ﬁ  lling phase). However, it 
contracts during the ﬁ  lling phase in patients with OAB. Therefore, muscarinic recep-
tor antagonists (antimuscarinic agents) are considered the mainstay of pharmacologic 
treatment for OAB (Erdem 2006).
Pharmacologic options
Muscarinic receptor antagonists inhibit the stimulation of the detrusor muscle by 
acetylcholine. Unfortunately, these agents are associated with undesirable anticho-
linergic adverse effects such as dry mouth, constipation, sedation, impaired cogni-
tive function, tachycardia and blurred vision (Erdem 2006). In addition, their use is 
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contraindicated in patients with narrow-angle glaucoma, 
urinary retention and gastric retention. These medications 
should be given with caution to the elderly, particularly 
those with gastroesophageal reﬂ  ux (GERD), constipation, 
or impaired cognitive function. It is also imperative to moni-
tor patient drug regimens for polypharmacy, potential drug 
interactions and other drug-related problems (Ouslander 
2002 and Erdem 2006).
Older antimuscarinic agents used for the management 
of OAB are oral oxybutynin (Ditropan® and Ditropan 
XL®, Ortho-McNeil), transdermal oxybutynin (Oxytrol®, 
Watson Pharmaceuticals) and oral tolterodine (Detrol® 
and Detrol LA®, Pﬁ  zer). In 2004, the United States Food 
and Drug Administration (FDA) approved three additional 
antimuscarinic agents for the management of OAB: tros-
pium (Sanctura®, Esprit/Indevus), solifenacin (VESIcare®, 
Yamanouchi/GlaxoSmithKline), and darifenacin (Enablex®, 
Novartis).
Oxybutynin and tolterodine
Oxybutynin is a relatively nonselective antimuscarinic agent 
which has been used for the management of OAB for over 30 
years (Product Information 2004a; Staskin 2006). Three for-
mulations are available: an immediate-release (IR) tablet taken 
twice daily (Ditropan®, Ortho-McNeil), an extended-release 
(ER) tablet taken once daily (Ditropan XL®, Ortho-McNeil), 
and a transdermal patch applied twice weekly (Oxytrol®, 
Watson Pharmaceuticals) (Abramovicz et al 2001, 2003).
Tolterodine is a competitive muscarinic receptor antago-
nist which gained FDA approval for the treatment of OAB in 
1998. Two formulations are available: an IR capsule taken 
twice daily (Detrol®, Pﬁ  zer) and an ER capsule taken once 
daily (Detrol LA®, Pﬁ  zer).
Oxybutynin and tolterodine have been commonly 
associated with adverse effects such as dry mouth, 
constipation, headache, dyspepsia, and dry eyes. Cognitive 
impairment, tachycardia and urinary retention may also 
occur. (Abramovicz et al 2001, 2003). The ER formulations 
of these agents have shown to be better tolerated, particu-
larly with respect to dry mouth, and more effective than the 
respective IR- formulations.
Oxybutynin and tolterodine have demonstrated their 
efﬁ  cacy in the management of OAB in multiple placebo-
controlled studies (Abramovicz et al 2003; Product Informa-
tion 2004a, 2005). Here we summarize four major trials that 
directly compare these two agents.
The Overactive Bladder: Judging Effective Control and 
Treatment (OBJECT) study was a prospective, randomized, 
double-blind, parallel-group study that compared the efﬁ  cacy 
and tolerability of oxybutynin-ER (10 mg once daily) to tolt-
erodine-IR (2 mg twice daily). A total of 378 patients were 
treated with one of the agents for 12 weeks. About 88% (332 
patients) completed the study. Results showed that oxybutynin-
ER was signiﬁ  cantly more effective than tolterodine-IR in 
weekly urge incontinence (p = 0.03), total incontinence (p =  
0.02) and micturition frequency episodes (p = 0.02). However, 
both agents signiﬁ  cantly improved symptoms of OAB from 
baseline as evaluated by the 3 outcomes measures (p   0.001). 
Adverse events were similar among all patients, with dry 
mouth being reported most commonly (28.1% oxybutynin-ER 
group, 33.2% tolterodine-IR group) (Appell et al 2001).
The Overactive Bladder: Performance of Extended-Re-
lease Agents (OPERA) trial was a 12-week double-blind 
study which randomized 790 women with OAB to receive 
either oxybutynin-ER 10 mg once daily or tolterodine-ER 4 
mg once daily. At 12 weeks, results showed similar improve-
ments in weekly urge urinary incontinence for both groups 
as well as a signiﬁ  cantly greater reduction in micturition 
frequency in the oxybutynin-ER group (p =  0.003). A greater 
percentage of women in the oxybutynin-ER group reported 
no episodes of urinary incontinence as compared to those in 
the tolterodine-ER group (23% vs 16.8%, p =  0.03). Toler-
ability was similar among all women, with the exception 
of dry mouth which was more commonly reported in the 
oxybutynin-ER group (p = 0.02) (Kiokno et al 2003).
The Antimuscarinic Clinical Effectiveness Trial (ACET) 
consisted of two identically designed open-label trials 
that randomized 1,289 participants with OAB to receive 
tolterodine-ER 2 mg or 4 mg once daily, or oxybutynin-ER 
5 mg or 10 mg once daily for 8 weeks. At the end of the 
trial, more patients in the tolterodine-ER groups reported 
an improvement in their bladder condition (60% toltero-
dine-ER 2 mg group, 70% tolterodine-ER 4 mg group, 59% 
oxybutynin-ER 5 mg group, and 60% oxybutynin-ER 10 mg 
group; p   0.01 vs oxybutynin-ER 10 mg). Furthermore, the 
response to therapy was greater in patients whose perception 
of bladder symptoms were moderate to severe at the begin-
ning of the trial. In terms of adverse effects, dose-dependent 
dry mouth was most commonly reported in both groups, but 
a lower severity was reported in the tolterodine-ER group 
(Sussman et al 2002).
Another study compared the efﬁ  cacy and safety of the 
transdermal oxybutynin to oral tolterodine-ER and placebo 
in the treatment of OAB. This 12-week, double-blind study 
randomized 361 patients to receive twice weekly transdermal 
oxybutynin (3.9 mg/day), tolterodine-ER 4 mg once daily, Clinical Interventions in Aging 2007:2(3) 339
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or placebo after withdrawal of previous treatments. At the 
end of the study, signiﬁ  cant reductions in the number of 
daily incontinence episodes (median change of –3 in the 
transdermal oxybutynin group, and −3 in the tolterodine-ER 
group vs −2 in the placebo group; p   0.05), increases in the 
average void volume (median change of 24 mL and 29 mL 
vs 5.5 mL; p   0.01), and improved quality of life based on 
questionnaire answers were observed. The most commonly 
reported adverse effects in the transdermal oxybutynin group 
were application site pruritus (14% vs 4% placebo) and ery-
thema (8.3% vs 1.7% placebo). The incidence of dry mouth 
in this groups was 4.1% as compared to 7.3% in the toltero-
dine-ER group and 1.7% in the placebo group (p   0.05) 
(Dmochowski et al 2003).
Trospium
In May 2004, trospium (Sanctura®, Esprit/Indevus) 
gained FDA approval for the management of OAB 
(Product Information 2004c). Trospium is a quaternary 
ammonium compound that has antimuscarinic properties 
(Figure 1). Trospium has high water solubility, low oral 
bioavailability and thus poor penetration into the central 
nervous system (CNS). These characteristics explain 
its lesser pronounced CNS side effects when compared 
to oxybutynin, a tertiary amine (Todorova et al 2001). 
Table 1 compares its pharmacokinetics to that of other 
agents for the management of OAB. The recommended 
dose is 20 mg twice daily at least 1 hour before meals or 
administered on an empty stomach. The dosage should be 
reduced to 20 mg once daily in patients with creatinine 
clearance (CrCl)  30 mL/min or patients  75 years of 
age (Product Information 2004c).
The efﬁ  cacy of trospium was evaluated in two mul-
ticenter, double-blind, randomized, placebo-controlled, 
12-week studies (Product Information 2004c; Zinner et 
al 2004; Rudy et al 2006a). Entry criteria required that 
patients have urge or mixed incontinence (with a pre-
dominance of urge), urge incontinence episodes of  7 
per week, and  70 micturitions per week. The efﬁ  cacy 
outcomes included improvement in urinary frequency, 
urge incontinence and urinary void volume. Of the 591 
patients who received trospium, 249 (42%) were  65 
years of age and 89 (15%) were  75 years of age (Product 
Information 2004c).
In one study, 262 patients received trospium 20 mg 
twice daily and 261 patients received placebo for 12 weeks 
(Table 2) (Zinner et al 2004). The majority of patients were 
Caucasian (85%) and female (74%) ranging in age between 
21 and 90 years. The mean change from baseline in urinary 
frequency was −1.3 in the patients who received placebo and 
−2.4 in those who received trospium (p   0.001). The mean 
change from baseline in urge incontinence episodes per week 
was -13.9 for the placebo group and −15.4 for the trospium 
group (p = 0.012). The mean change from baseline in urinary 
void volume was +7.7 mL in patients who received placebo 
and +32.1 mL in those who received trospium (p  0.001). 
About 8.8% of those in trospium group and 5.7% of placebo 
group discontinued from the study due to adverse events.
In another study, a total of 329 patients received trospium 
20 mg twice daily and 329 patients received placebo for 12 
weeks (Table 2) (Rudy et al 2006a). The majority of patients 
were Caucasian (88%) and female (82%) ranging in age 
between 19 and 94 years. The mean change from baseline 
in urinary frequency was −1.8 in the patients who received 
placebo and −2.7 in those who received trospium (p   0.001). 



















Figure 1 Chemical structures of trospium, solifenacin and darifenacin.Clinical Interventions in Aging 2007:2(3) 340
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per week was −12.1 for the placebo group and −16.1 for the 
trospium group (p   0.001). The mean change in urinary 
void volume was +9.4 mL in patients who received placebo 
and +35.6 mL in those who received trospium (p   0.001). 
Efﬁ  cacy of trospium could be seen within 7 days of therapy 
(Rudy et al 2006b).
Dry mouth and constipation were reported in 20% and 
10% of patients in the clinical trials, respectively. Other 
adverse events reported were headache (4%), fatigue (2%), 
dyspepsia (1%), and ﬂ  atulence (1%). Drug interactions 
may occur when coadministing trospium with drugs that 
are renally eliminated by active tubular secretion (digoxin, 
procainamide, pancuronium, morphine, vancomycin, metfor-
min, and tenofovir). Due to competition in renal elimination, 
serum concentration of trospium and/or the coadministered 
drug can increase (Product Information 2004c).
Table 2 Efﬁ  cacy of trospium in the management of overactive bladder (Product Information 2004c)
Efﬁ  cacy endpoint  Zinner et al 2004    Rudy et al 2006a 
 Placebo  (n  = 256) Trospium  (n  = 253) Placebo  (n  = 325) Trospium  (n  = 323)
Urinary frequency/24 hours
 Mean  baseline  12.9  12.7  13.2  12.9
  Mean change from baseline  −1.3  −2.4  −1.8  −2.7
Urge incontinence episodes/weeka
 Mean  baseline  30.1  27.3  27.3  26.9
  Mean change from baseline  −13.9  −15.4  −12.1  −16.1
Urinary void volume (mL)
 Mean  baseline  156.6  155.1  154.6  154.8
  Mean change from baseline  +7.7  +32.1  +9.4  +35.6
aPlacebo n = 253, trospium n = 248 in Zinner et al (2004).
Placebo n = 320, trospium n = 319 in Rudy et al (2006a).
Table 1 Pharmacokinetics of antimuscarinic agents approved for overactive bladder
 Oxybutynin  Tolterodine  Trospium  Solifenacin  Darifenacin
F (%)  IR and ER: 6%; no  IR and ER: 77%; no   10%; high fat meals  90%; no change  15–20%; no 
  change with food  change with food  decrease absorption  with food   change with 
     by  70–80%    food
Cmax  IR (5 mg): 3.6 to 7.8  IR (4  mg): 1.6 to 10  3.5  32.3 (5  mg)  2.0 (7.5  mg)
(ng/mL),  ER (10 mg): 1.0−1.8  ER (4  mg): 1.3    62.9 (10  mg)  5.8 (15  mg)
mean  Transdermal (single
  −dose): 3.0 to 3.4
Tmax (hr),  IR (5 mg): 0.65 to 0.89  IR (4  mg): 1.4 to 1.6  5–6  3−8 7−8
mean  ER (10 mg): 11.8 to 12.7  ER (4  mg): 4
 Transdermal  (single
  -dose):36 to 48 
T1/2 (hr),  IR (5 mg): 1.1 to 2.3  IR (4  mg): 2.0 to 6.5  18  45–68  13−19
mean  ER (10 mg): 12.4−13.2  ER (4  mg): 8.4
 Transdermal  (single-
  dose): 7 to 8 after removal
CYP450  IR and ER: 3A4  2D6  CYP450 not involved  3A4  3A4, 2D6
Metabolism 
Excretion  Extensively metabolized;  Urine 77%; feces  Feces 85%  Urine 70%, feces  Urine 60%, feces
   0.1% excreted in the  17%  urine 6%
 urine
Vd (L), mean  193 113  395  600  163
Protein binding  91−93%  96%  50–85% 98% 98%
Pharmacokinetic  No  Mean serum   No  20−25% higher in  NR
change in geriatrics    concentrations may     Cmax, drug
   be higher   exposure and t1/2
Abbreviations: F, Bioavz,ailability; Cmax, Maximum observed plasma concentration; Tmax, Time of occurrence of Cmax; T1/2, Half life; CYP450, Cytochrome P450 liver enzymes; 
Vd, Volume of distribution; IR, Immediate release; ER, Extended release; NR, Not reported.Clinical Interventions in Aging 2007:2(3) 341
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Solifenacin
Solifenacin (VESIcare®, Yamanouchi/GlaxoSmithKline) is 
a muscarinic blocker for the management of OAB. It is a 
competitive, selective M1 and M3 receptor antagonist. In 
animal studies, the selectivity of solifenacin for the bladder 
over the salivary glands was greater than that of tolterodine, 
oxybutynin, darifenacin or atropine (Simpson et al 2005). The 
starting dosage is 5 mg daily with or without food, and may 
be titrated to 10 mg daily as tolerated. A maximum daily dose 
of 5 mg is recommended in patients with CrCl  30 mL/min, 
with Child-Pugh B hepatic impairment, or receiving potent 
cytochrome P450 enzyme (CYP) 3A4 inhibitors, such as 
ketoconazole (Product Information 2004d).
Four 12-week, double-blind, randomized, placebo-
controlled, parallel group, multicenter clinical trials 
evaluated the efﬁ  cacy and safety of solifenacin for the 
management of OAB (Gittelman et al 2003; Cardozo et al 
2004; Chapple et al 2004; Haab et al 2005). All patients 
were required to have symptoms of OAB for  3 months. 
These studies involved 3027 patients (1811 on solifenacin 
and 1216 on placebo), and approximately 90% of these 
patients completed the studies. The majority of patients 
were Caucasian (93%) and female (80%) with a mean 
age of 58 years. At 12-weeks, the mean reduction in the 
number of micturitions per 24 hours was greater with 
solifenacin 5 mg (−2.3; p   0.001) and solifenacin 10 mg 
(−2.7; p   0.001) as compared to placebo (−1.4). The mean 
reduction in the number of daily incontinence episodes 
was greater with solifenacin 5 mg (−1.5; p   0.001) 
and solifenacin 10 mg (−1.8; p   0.001) as compared to 
placebo (−1.1). The mean increase in the volume voided 
per micturition was signiﬁ  cantly greater with solifenacin 
5 mg (+32.3 mL; p   0.001) and solifenacin 10 mg (+42.5 
mL; p   0.001) compared to placebo (+8.5 mL). Similar 
safety and effectiveness were observed between older 
(623 patients  65 years and 189 patients  75 years) and 
younger patients (Product Information 2004d). Table 3 
reports the major results from four individual 12-week 
clinical trials.
Solifenacin demonstrated similar efficacy when 
compared to tolterodine-IR 2 mg twice daily in a random-
ized, double-blind, 12-week trial (Chapple et al 2004). 
Compared to baseline, the mean change in number of 
urgency episodes per 24 hours were: −1.41 (placebo); −2.85 
(solifenacin 5 mg);  −3.07 (solifenacin 10 mg) and −2.05 
(tolterodine-IR). The changes in episodes of incontinence 
were: −0.76 (placebo), −1.42 (solifenacin 5 mg), −1.45 
(solifenacin 10 mg) and −1.14 (tolterodine-IR). The mean 
number of voids in 24 hours were: −1.20 (placebo), −2.19 
(solifenacin 5 mg), −2.61 (solifenacin 10 mg), and −1.88 
(tolterodine-IR). The mean volume voided per micturition 
was signiﬁ  cantly higher with all three active treatments (48 
to 41 mL). The most common side effects reported were 
dry mouth (solifenacin 14%–21%, tolterodine-IR 19%), 
constipation (solifenacin 7%–8%, tolterodine-IR 3%) and 
blurred vision (solifenacin 4%–6%, tolterodine-IR 2%). 
Table 3 Efﬁ  cacy of solifenacin in the management of overactive bladder (Product Information 2004d)
Efﬁ  cacy Endpoint  Chapple et al 2004    Cardozo et al 2004    Gittelman et al 2003 
  Placebo Solifenacin    Placebo Solifenacin  Placebo Solifenacin  Placebo Solifenacin
    5 mg  10 mg     5 mg  10 mg      10 mg  10 mg
  (n = 253)  (n = 266)  (n = 264)  (n = 281)  (n = 286)  (n = 290)  (n = 309)  (n = 306)  (n = 295)  (n = 298)
Urinary frequency
/24 hours
  Mean  baseline  12.2  12.1 12.3  12.3  12.1 12.1  11.5  11.7 11.8  11.5




  Mean  baseline  18.9  18.2 18.2  22.4  18.2 19.6  21.0  21.7 20.3  20.3




  Mean  baseline  143.8  149.6 147.2  147.2  148.5 145.9  190.3  183.5 175.7  174.1
  Mean  change  from  +7.4 +32.9 +39.2  +11.3  +31.8 +36.6  +2.7  +47.2 +13.0  +46.4
 baseline
aFor comparison purpose, data derived from multiplying the numbers of incontinence episodes per 24 hours (Product Information 2004d) by 7.Clinical Interventions in Aging 2007:2(3) 342
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In another study, solifenacin showed greater efﬁ  cacy to 
tolterodine-ER 4 mg once daily in decreasing urgency 
episodes, incontinence, and pad usage and increasing the 
volume voided per micturition (Chapple et al 2005). More 
patients in the solifenacin group reported improvements 
in perception of bladder symptoms.
The long-term efﬁ  cacy and safety of solifenacin were 
demonstrated in a 52-week study (12-week phase III study 
followed by a 40-week open-label extension study) (Haab 
et al 2005). Eighty-one percent of 1637 patients completed 
the study with 4.7% of patients discontinuing treatment due 
to adverse events. Improvements in OAB symptoms were 
noted for all patients for up to 52 weeks of treatment. Patient 
satisfaction with solifenacin tolerability and efﬁ  cacy was high 
at 85% and 74%, respectively. Solifenacin also signiﬁ  cantly 
improved the quality of life in patients with OAB symptoms 
after 12 weeks of treatment, with further improvements dur-
ing long-term administration up to 1 year (Haab et al 2005; 
Kelleher et al 2005).
Common side effects reported were dry mouth (11%, 
28%), constipation (5%, 13%), blurred vision (4%, 5%), 
and dyspepsia (1%, 4%) for solifenacin 5 mg and solif-
enacin 10 mg, respectively (Product Information 2004d). 
Patients should be advised to contact their physician if they 
experience severe abdominal pain or become constipated 
for 3 or more days. Drug Interactions must be monitored 
between solifenacin and potent CYP3A4 inhibitors (eg, keto-
conazole, itraconazole, ritonavir, nelﬁ  navir, clarithromycin, 
and nefazodone).
Darifenacin
In December 2004, darifenacin (Enablex®, Novartis), 
another muscarinic receptor antagonist, was approved for 
the management of OAB (Product Information 2004b). It 
has a greater affinity for the bladder-specific M3 recep-
tor. The recommended starting dose is 7.5 mg once daily 
with or without food. After two weeks of therapy, the 
dose may be increased to 15 mg once daily if tolerated. 
The maximum daily dose of 7.5 mg is recommended in 
patients with moderate hepatic impairment or in those 
taking potent CYP3A4 inhibitors (eg, ketoconazole, 
itraconazole, ritonavir, nelfinavir, clarithromycin, and 
nefazodone) concomitantly. Darifenacin should be ad-
ministered with caution to patients with severe hepatic 
impairment. Patients should swallow the whole tablets 
without chewing, crushing or dividing.
Four randomized, double-blind, placebo-controlled, mul-
ticenter, 12-week studies evaluated the efﬁ  cacy and safety 
Table 4 Efﬁ  cacy of darifenacin in the management of overactive bladder (Product Information 2004b)
Efﬁ  cacy endpoint  Haab et al 2004    Hill et al 2006    Steers et al 2005 
  Placebo Darifenacin    Placebo Darifenacin    Placebo Darifenacin  Placebo Darifenacin
    7.5 mg  15 mg    7.5 mg  15 mg    15 mg    7.5/15 mg
  (n = 164) (n = 229)  (n = 115) (n = 109) (n = 108)  (n = 107) (n = 115) (n = 112)  (n = 127) (n = 268)
Urinary frequency/
24 hours
  Median  baseline  10.1 10.1  10.1 10.1 10.3  11.0 10.4 10.5  10.4 9.9
  Median change from   −0.8  −1.6  −1.7  −1.1  −1.7  −1.9  −1.2  −1.9  −1.9  −1.9
 baseline




  Median  baseline  16.6 16.3  17.0 16.1 14.0  17.3 15.5 16.2  14.0 16.0
  Median change from   −7.6  −9.0  −10.4  −5.9  −10.4  −8.1  −9.0  −11.4  −6.0  −8.2
 baseline
  Median difference to   –  −1.5  −2.1  −  −2.8  −4.3  −  −2.4  −  −1.4
 placebo
Urinary void volume (mL)
  Median  baseline  162.4 160.2  151.8 162.2 161.7  157.3 147.1 155.0  177.2 173.7
  Median change from   +7.6  +14.9  +30.9  +7.1  +16.8  +23.6  +4.6  +26.7  +6.6  +18.8
 baseline
  Median difference to   − +9.1 +20.7  − +9.2 +16.6  − +20.1  − +13.3
 placeboClinical Interventions in Aging 2007:2(3) 343
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of darifenacin (Haab et al 2004; Steers et al 2005; Chapple 
et al 2005; Hill et al 2006). The majority of patients were 
white (94%) and female (84%), with a mean age of 58 years 
(range: 19 to 93 years). All patients had  8 micturitions and 
 1 episode of urinary urgency per day and  5 episodes of 
urge urinary incontinence per week for at least six months. 
A signiﬁ  cant decrease in weekly urge incontinence from 
baseline was observed in all four studies. Reductions in 
weekly incontinence were observed within the ﬁ  rst 2 weeks 
in patients treated with darifenacin. Table 4 reports the major 
results from four individual 12-week clinical trials (Product 
Information 2004b).
An analysis of pooled data from three phase III, multi-
center, double-blind, 12-week clinical trials (n =  1059 adults, 
85% women) conﬁ  rmed the efﬁ  cacy and safety of darifenacin 
in OAB. Darifenacin reduced the number of weekly inconti-
nence episodes by 8.8 (median) at 7.5 mg, and 10.6 (median) 
at 15 mg (both p   0.01 versus placebo). Darifenacin also 
reduced the frequency and severity of urgency, voiding 
frequency, and number of signiﬁ  cant leaks, and increased 
bladder capacity (Chapple et al 2005).
Darifenacin provides comparable efﬁ  cacy with improved 
tolerability when compared to oxybutynin. A double-blind 
study randomized 76 adults with OAB to receive 2 weeks each 
of darifenacin 15 and 30 mg once daily, oxybutynin 5 mg three 
times daily and placebo, in random sequence at 10-day intervals. 
Darifenacin and oxybutynin signiﬁ  cantly reduced incontinence 
episodes, and the number/severity of urgency episodes (all 
Table 5 Considerations for individualizing therapy for overactive bladder (Product Information 2004a, 2004b, 2004c, 2004d)
 Oxybutynin  Tolterodine  Trospium  Solifenacin  Darifenacin
Usual Adult Dosage  IR: 5 mg orally 2 or 3  IR: 2 mg orally twice daily  20 mg twice daily  5 to 10 mg  7.5 to 15 mg
  times daily  ER: 4 mg orally once daily  Age  75: 20  mg   once daily   once daily
  ER: 5 mg or 10 mg    once daily
  orally once daily
  (same time each day)
  Transdermal: 1 patch
  (3.9 mg/day) applied twice
  weekly (every 3 to 4 days)
Hepatic Insufﬁ  ciency  --  IR: 1 mg orally twice daily  --  Moderate: 5  mg   Moderate: 7.5 mg
    ER: 2 mg orally once daily    once daily  once daily
        Severe: avoid use  Severe: avoid use
Renal Insufﬁ  ciency  --  CrCl 10 to 30ml/min  CrCl  30 ml/min:   CrCl  30 ml/min:  --
    IR: 1 mg orally twice daily  20  mg once daily  5  mg once daily
    ER: 2 mg orally once daily
CYP Interactions  Belladon,  Clarithromycin,  --  3A4 inhibitors  2D6 & 3A4 inhibitors 
  Belladona Alkaloids,  Cyclosporine,    (see text)  (see text)
 Cisapride,  Erythromycin,
 Clomipramine,  Fluoxetine,
 Ketoconazole  Itraconazole,
   Ketoconazole,
   Miconazole,
   Vinblastine,
   Warfarin
Comments  Take with or without  Take with or   Take before  Take with or   Take with or
  food.  without food.  meals or on empty  without food.  without food
  Swallow whole. Do  Take with water  stomach  Take with water  Take with water
  not crush, break, or chew  or liquids.    or liquids  or liquids
    Swallow whole. Do    Swallow whole.  Swallow whole.
    not crush,       Do not crush,
    break, or chew      break, or chew
Costa Average  generic:  Detrol®: $82.20  $100.20  $99.60
 $22.80  $105.60 
(1 month  Ditropan®: $64.20  Detrol LA®:
supply at the  Ditropan XL®: $91.80
lowest $94.20
recommended Oxytrol®:
adult dosage)  $88.16
aFrom Rizack (2005).Clinical Interventions in Aging 2007:2(3) 344
Lam and Hilas
p  0.05 vs placebo). Improvements in symptoms with dari-
fenacin were dose-dependent. Dry mouth occurred in 13%, 
34% and 36% in the darifenacin 15 mg, 30 mg and oxybutynin 
groups, respectively. Constipation occurred more commonly in 
darifenacin groups, 10%, 21% and 8%, respectively. Patients 
reported blurred vision or dizziness with oxybutynin only (3% 
and 2%, respectively) (Zinner et al 2005).
In all ﬁ  xed-dose phase III studies combined, 3.3% of 
patients treated with darifenacin discontinued due to adverse 
events versus 2.6% in placebo. Dry mouth and constipation 
were the leading causes of treatment discontinuation. The 
most common adverse effects associated with darifenacin 
7.5 mg and 15 mg, respectively, were: dry mouth (20%, 35%), 
constipation (15%, 21%), dyspepsia (3%, 8%), urinary tract 
infection (5%, 5%) and abdominal pain (2%, 4%). Darifenacin 
is extensively metabolized by CYP2D6 and CYP3A4. Daily 
coadministration of darifenacin 30 mg with a potent CYP2D6 
inhibitor (eg, paroxetine) can lead to a 33% increase of da-
rifenacin drug exposure at steady state (Product Information 
2004b).
Similar to other anticholinergic drugs, all newer agents 
for the management of OAB (trospium, solifenacin and dari-
fenacin) are contraindicated in patients with urinary retention, 
gastric retention, or uncontrolled narrow-angle glaucoma 
(Product Information 2004b). Use these agents cautiously in 
patients with clinically signiﬁ  cant bladder outﬂ  ow obstruction, 
ulcerative colitis, intestinal atony, gastrointestinal obstruc-
tive disorders, myasthenia gravis, narrow-angle glaucoma, 
and moderate/severe hepatic dysfunction. Patients should be 
informed of possible anticholinergic side effects, such as heat 
prostration (fever and heat stroke due to decreased sweating in 
hot environment), dry mouth, constipation, dry eyes, urinary 
retention, dizziness and blurred vision. Use these agents only 
if the potential beneﬁ  ts outweigh the risks associated with 
therapy (Product Information 2004b).
Summary
Antimuscarinic agents are the mainstay of pharmacologic 
treatment of OAB. Currently available drugs indicated 
for the treatment of OAB with symptoms of urge urinary 
incontinence, urgency and frequency are: oxybutynin, tolt-
erodine, trospium, solifenacin and darifenacin. All of these 
agents have demonstrated efﬁ  cacy and safety in placebo-
controlled clinical trials. Additionally, they have similar 
contraindications, precautions and side effect proﬁ  les (dry 
mouth, constipation and other anticholinergic effects). Man-
agement of urinary symptoms associated with OAB should 
be individualized based on patient renal/hepatic function, 
medical conditions and concurrent medication use. Dosing 
convenience and drug cost should be considered to promote 
patient compliance (Table 5). Anticholinergic side effects 
should be monitor closely, especially in the elderly and those 
who take other anticholinergic agents concomitantly. Ideally, 
patient medication regimen should be reviewed periodically 
for therapeutic efﬁ  cacy, drug toxicity, clinical signiﬁ  cant 
drug interactions and other drug-related problems.
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